CEL-SCI Corporation Announces New Jersey Medical School and Veteran Affairs Medical Center is Ready to Commence Enrollment for Phase III Clinical Trial of Multikine in Head and Neck Cancer

CEL-SCI Corporation CVM announced today that, following completion of a successful site initiation visit, the New Jersey Medical School and Veterans Affairs Medical Center is ready to begin immediate enrollment of qualified patients that desire to participate in its Phase III clinical trial of Multikine®, the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer.